Wednesday, July 8, 2026

Patent intelligence · US

US 10538530

Vasopressin receptor antagonists and products and methods related thereto

granted A61PA61P25/00A61P25/18A61P25/20
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 38
Patent details — US 10538530
Jurisdiction
US
Status
granted
Grant date
Jan 21, 2020
Expiration
Jan 16, 2040
Claims
104
CPC classes
A61P, A61P25/00, A61P25/18, A61P25/20
View on Google Patents ↗

Quick answer

US 10538530 (Vasopressin receptor antagonists and products and methods related thereto) is held by BLACKTHORN THERAPEUTICS, INC.. Status: granted. Granted Jan 21, 2020. Expires Jan 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
104
CPC classes
A61P, A61P25/00, A61P25/18, A61P25/20, A61P25/22, A61P25/24

More from BLACKTHORN THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12343394

    CD38 modulating antibody agents

    BLACK BELT THERAPEUTICS LIMITED · Expires Jun 26, 2045

    granted
  2. US 12325699

    Antibacterial compounds

    BLACKSMITH MEDICINES, INC. · Expires Jun 5, 2045

    granted
  3. US 12304964

    CD38 modulating antibody

    BLACK BELT THERAPEUTICS LIMITED · Expires May 15, 2045

    granted
  4. US 12187754

    LpxC inhibitors and uses thereof

    BLACKSMITH MEDICINES, INC. · Expires Jan 2, 2045

    granted
  5. US 12161717

    CD38 modulating antibody agents

    BLACK BELT THERAPEUTICS LIMITED · Expires Dec 5, 2044

    granted
  6. US 12162949

    CD38 antibody

    BLACK BELT THERAPEUTICS LIMITED · Expires Dec 5, 2044

    granted
  7. US 11897873

    Kappa opioid receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Expires Feb 8, 2044

    granted
  8. US 11780930

    CD38 modulating antibody

    BLACK BELT THERAPEUTICS LIMITED · Expires Oct 5, 2043

    granted

Frequently asked questions

What is US patent 10538530?

US 10538530 (Vasopressin receptor antagonists and products and methods related thereto) is held by BLACKTHORN THERAPEUTICS, INC.. Status: granted. Granted Jan 21, 2020. Expires Jan 16, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10538530?

BLACKTHORN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.

When does US 10538530 expire?

Our index shows an expiration date of Jan 16, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.